A few eyebrows were raised in earlier this year when Bristol Myers Squibb (BMS) announced the details of a noteworthy new partnership with investment firm Bain Capital.
The agreement will see the creation of an entirely new, fully independent and as yet unnamed, biopharmaceutical business focused on developing therapies for autoimmune diseases that “address significant unmet needs of patients”.[1]
Bain Capital is backing the venture as the lead investor in a sizeable $300 million financing commitment. For its part, BMS is contributing a ready-made pipeline of five licenced immunology assets consisting of three clinical-stage and two Phase 1 ready investigational medicines that it says “target promising mechanisms in autoimmune diseases”. BMS will retain an equity stake of nearly 20% and earn royalties and milestone payments as and when the therapies successfully progress through the development pathway.
Private-equity (PE) backed investment in biopharmaceuticals is nothing new – and certainly not for Bain Capital, which earlier this year announced the acquisition of the Mitsubishi Tanabe Pharma Corporation of Japan, originally founded in 1678. However, the move is something of a departure from more traditional PE models that are typically categorised by the provision of growth capital or a leveraged ‘buy-and-build’ approach. In this case, the BMS assets have been carved out into a separate entity and provided with a level of funding and focus that is designed to accelerate momentum for therapies that are in clinical trial or at early-stage development.
Although it has relinquished a degree of control over potentially promising assets, BMS has the benefit of continuing to hold a stake in the game while being freed up to concentrate R&D efforts on other priority therapies. For the private equity (PE) sector, the appeal of this approach can be distilled down to the fundamentals of minimising risk and maximising returns. Optimising this balance is crucial in a sector such as biopharmaceuticals, which can be something of a conundrum for investors, who are at once drawn to the potential of future blockbuster molecules but all too aware that the chance of successfully moving from Phase I to approval can be as low as 8%.
For these reasons, the logic of this ‘carve out’ model makes sense. But in the context of such a shift, where greater emphasis is placed on risk mitigation and management within the drug development cycle, it also follows that tougher questions must be asked about the problematic clinical trial approaches that continue to undermine study integrity, hindering development schedules and placing regulatory approval into serious jeopardy. Specifically, the continued adoption of outdated methods of monitoring medication adherence such as pill count and patient self-report appear to run counter to wider ambitions to apply greater efficiency, accuracy and reliability to this undoubtedly investment-intensive process.
Despite these legacy approaches continuing to dominate monitoring within trial settings, they are fundamentally flawed as vehicles for generating solid data on medication adherence. Open to bias and human error, they fall short when it comes to providing a full and precise picture of the relationship between exposure to a candidate therapy and its efficacy and safety at a given dose.
By contrast, employing digital medication monitoring tools allows for a far more robust, accurate evaluation of this relationship. These tools not only strengthen study power, they also help avoid in-trial complications and even safeguard against the risk of the trial failing altogether. In essence, employing digitally enhanced monitoring is a key de-risking strategy for clinical trials, insuring sponsors against hidden weaknesses that have the potential to compromise the whole process while providing assurances that development programs are built on the strong foundations of accurate dosing data and reliable evaluations of efficacy and safety.
As the cultural practices of private equity increasingly infuse the biopharmaceutical sector, it is possible that change will accelerate in this direction. Existing points of weakness within the clinical trial landscape, such as non-digital adherence monitoring, are already being identified and addressed in the interests of efficiency, optimisation and progress, and with a view to eliminating wasted time, effort and cost.
For biopharma companies, looking ahead to a future where development pathways are optimised and de-risked in this way raises important and interesting questions over how best to focus R&D programmes. The natural symbiosis with PE partners will remain, but it is possible that maintaining more in-house ownership of the process will hold greater appeal if the instability surrounding clinical trials can be replaced by firmer footings and underwritten by more robust data-gathering processes.
However this future plays out, and whatever the models adopted by biopharma companies and their investment partners, there is clearly a continued need to address risk throughout the entire development cycle in order to stand a better chance of reaping the rewards from the many promising therapies in biopharmaceutical pipelines.
Establishing hard evidence for your trial…
AARDEX has a best practice methodology, independent of any device package or software platform. Utilising our expertise and experience in medication adherence and patient compliance we acquire, monitor, analyse, guide and interpret data to deliver absolute clarity and bring confidence to sponsors, trialists, and ultimately, patients.
AARDEX is the only mature, robust and proven adherence solution on the market today, one that maximises the reward, mitigates the risk and delivers resolution for your clinical trial. All delivered with the clarity, integrity and certainty you need to proceed with complete confidence in the exposure-response.
[1] https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-and-Bain-Capital-Create-New-Company-Dedicated-to-Developing-Innovative-Immunology-Therapies-that-Address-the-Unmet-Medical-Needs-of-Patients/default.aspx
